HRP20250166T1 - Mini tablete melatonina i način proizvodnje istih - Google Patents

Mini tablete melatonina i način proizvodnje istih Download PDF

Info

Publication number
HRP20250166T1
HRP20250166T1 HRP20250166TT HRP20250166T HRP20250166T1 HR P20250166 T1 HRP20250166 T1 HR P20250166T1 HR P20250166T T HRP20250166T T HR P20250166TT HR P20250166 T HRP20250166 T HR P20250166T HR P20250166 T1 HRP20250166 T1 HR P20250166T1
Authority
HR
Croatia
Prior art keywords
tablet
mini
melatonin
sustained
coating
Prior art date
Application number
HRP20250166TT
Other languages
English (en)
Croatian (hr)
Inventor
Moshe Laudon
Nava Zisapel
Original Assignee
Neurim Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57482481&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20250166(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurim Pharmaceuticals Ltd. filed Critical Neurim Pharmaceuticals Ltd.
Publication of HRP20250166T1 publication Critical patent/HRP20250166T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20250166TT 2016-10-31 2016-11-29 Mini tablete melatonina i način proizvodnje istih HRP20250166T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662415014P 2016-10-31 2016-10-31
EP20195788.3A EP3777842B1 (en) 2016-10-31 2016-11-29 Melatonin mini-tablets and method of manufacturing the same

Publications (1)

Publication Number Publication Date
HRP20250166T1 true HRP20250166T1 (hr) 2025-05-09

Family

ID=57482481

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20250166TT HRP20250166T1 (hr) 2016-10-31 2016-11-29 Mini tablete melatonina i način proizvodnje istih
HRP20201722TT HRP20201722T1 (hr) 2016-10-31 2016-11-29 Minitablete melatonina i postupak njihove proizvodnje

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20201722TT HRP20201722T1 (hr) 2016-10-31 2016-11-29 Minitablete melatonina i postupak njihove proizvodnje

Country Status (25)

Country Link
US (2) US10722494B2 (enExample)
EP (3) EP4474012A3 (enExample)
JP (1) JP6830156B2 (enExample)
KR (1) KR102167190B1 (enExample)
CN (1) CN109922795B (enExample)
AU (6) AU2016426598C1 (enExample)
CA (1) CA3040027C (enExample)
CY (1) CY1123449T1 (enExample)
DK (2) DK3337462T3 (enExample)
ES (2) ES3009413T3 (enExample)
FI (1) FI3777842T3 (enExample)
HR (2) HRP20250166T1 (enExample)
HU (2) HUE051362T2 (enExample)
IL (1) IL262537B (enExample)
LT (2) LT3777842T (enExample)
MX (1) MX386987B (enExample)
NZ (1) NZ747702A (enExample)
PL (2) PL3337462T3 (enExample)
PT (2) PT3337462T (enExample)
RS (2) RS66471B1 (enExample)
SG (1) SG11201903829PA (enExample)
SI (2) SI3777842T1 (enExample)
SM (2) SMT202500046T1 (enExample)
TW (1) TWI787164B (enExample)
WO (1) WO2018078429A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220125733A1 (en) * 2020-10-23 2022-04-28 Atoz Pharmaceuticals Pvt Ltd Nongranulated compressed tablets of mesalamine, and process of preparation thereof
KR20230017814A (ko) * 2020-10-26 2023-02-06 일동제약(주) 옥수수불검화추출물을 포함하는 소형화된 경구투여 제제의 제조방법 및 이에 따라 제조된 소형화 제제
CN120076789A (zh) 2022-10-14 2025-05-30 雀巢产品有限公司 缓释褪黑激素组合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600723A (en) 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
ES2134789T3 (es) 1991-05-09 1999-10-16 Neurim Pharma 1991 Composiciones que contienen melatonina.
ATE141051T1 (de) 1992-04-07 1996-08-15 Neurim Pharma 1991 Verwendung von melatonin zur herstellung eines arzneimittels zur behandlung der gutartigen prostatahyperplasie
US5449683A (en) 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
AU7550994A (en) * 1993-07-26 1995-02-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Sustained release oral compositions containing melatonin
PL183148B1 (pl) * 1995-02-01 2002-05-31 Neurim Pharma 1991 Zastosowanie melatoniny do wytwarzania leku do leczenia zależności, nałogu stosowania lub tolerancji na benzodiazepiny oraz zastosowanie melatoniny do wytwarzania leku do zapobiegania zależności, nałogu stosowania lub tolerancji na benzodiazepiny
US6469044B1 (en) 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
FR2762513B1 (fr) * 1997-04-23 2003-08-22 Permatec Pharma Ag Comprimes bioadhesifs
CA2346001C (en) 1998-10-01 2003-12-30 Elan Pharma International, Limited Controlled release nanoparticulate compositions
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
CN1414851A (zh) * 2000-01-05 2003-04-30 纽里姆药品(1991)有限公司 用于治疗对抗高血压药的抗药性和相关病症的方法和制剂
US6458384B2 (en) * 2000-02-23 2002-10-01 Impetus Ag Pharmaceutical with predetermined activity profile
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
IL149377A (en) 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
KR20030016215A (ko) * 2002-07-05 2003-02-26 뉴림 파머슈티칼스 (1991) 리미티드 항고혈압제에 대한 내성 및 관련 질환의 치료를 위한 방법및 제형
EP1592453A1 (en) * 2003-01-28 2005-11-09 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
JP2007517040A (ja) 2003-12-24 2007-06-28 セプレイコー インコーポレイテッド 睡眠の質を改善するためのメラトニン併用療法
FR2889811B1 (fr) * 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
DE102006006532B4 (de) 2006-02-10 2007-11-08 Biogenerics Pharma Gmbh Pharmazeutische Zubereitung
WO2008148015A1 (en) 2007-05-24 2008-12-04 The Trustees Of Columbia University In The City Of New York Sustained release formulation of melatonin
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
RU2488388C1 (ru) * 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
DK2949322T3 (en) 2014-05-28 2018-07-23 Valpharma S P A FORMULATION FOR ORAL ADMINISTRATION COMPREHENSIVE MELATONIN IN STABLE FORM AND PROCEDURE FOR PREPARING THEREOF

Also Published As

Publication number Publication date
SG11201903829PA (en) 2019-05-30
AU2016426598A1 (en) 2018-05-17
EP3777842B1 (en) 2024-12-11
ES2828034T3 (es) 2021-05-25
US10869857B2 (en) 2020-12-22
CN109922795A (zh) 2019-06-21
AU2019101470B4 (en) 2020-06-25
CY1123449T1 (el) 2022-03-24
TWI787164B (zh) 2022-12-21
AU2025234204A1 (en) 2025-10-09
RS66471B1 (sr) 2025-03-31
FI3777842T3 (fi) 2025-02-11
PL3337462T3 (pl) 2021-01-25
JP6830156B2 (ja) 2021-02-17
MX386987B (es) 2025-03-19
WO2018078429A1 (en) 2018-05-03
ES3009413T3 (en) 2025-03-26
EP4474012A3 (en) 2025-03-12
NZ747702A (en) 2022-08-26
MX2019004736A (es) 2019-06-17
AU2021200268A1 (en) 2021-03-18
HUE070190T2 (hu) 2025-05-28
CA3040027A1 (en) 2018-05-03
EP3337462A1 (en) 2018-06-27
IL262537B (en) 2021-03-25
SI3777842T1 (sl) 2025-03-31
LT3777842T (lt) 2025-04-10
EP4474012A2 (en) 2024-12-11
NZ782840A (en) 2025-02-28
AU2019101470A4 (en) 2020-01-16
DK3777842T3 (da) 2025-02-03
CA3040027C (en) 2023-08-15
EP3777842A1 (en) 2021-02-17
EP3337462B1 (en) 2020-09-30
AU2016426598C1 (en) 2024-02-08
KR20190014512A (ko) 2019-02-12
PL3777842T3 (pl) 2025-05-12
US20200306227A1 (en) 2020-10-01
AU2016426598B2 (en) 2018-11-01
PT3337462T (pt) 2020-10-30
US10722494B2 (en) 2020-07-28
SMT202500046T1 (it) 2025-03-12
AU2019200479A1 (en) 2019-02-14
IL262537A (en) 2018-12-31
TW201817418A (zh) 2018-05-16
JP2019533672A (ja) 2019-11-21
AU2019200479B2 (en) 2020-10-22
KR102167190B1 (ko) 2020-10-19
PT3777842T (pt) 2025-02-11
CN109922795B (zh) 2021-10-08
SMT202000575T1 (it) 2021-01-05
AU2023202003A1 (en) 2023-05-04
HUE051362T2 (hu) 2021-03-01
LT3337462T (lt) 2021-01-11
DK3337462T3 (da) 2020-10-12
HRP20201722T1 (hr) 2021-03-05
SI3337462T1 (sl) 2021-01-29
RS61024B1 (sr) 2020-12-31
US20190060277A1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
Lee et al. Effects of systemic administration of ibuprofen on stress response in a rat model of post-traumatic stress disorder
Whitley et al. Prevention and treatment of influenza in high‐risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents
NI202100009A (es) Métodos para reducir la necesidad de revascu
BRPI0716436B8 (pt) sistema de liberação controlada e método para fabricação do mesmo
FI3902547T3 (fi) Csf1r-inhibiittoreita käytettäväksi syövän hoitamisessa
DellaGioia et al. Bupropion pre-treatment of endotoxin-induced depressive symptoms
US20120276017A1 (en) Methods and Compositions for Treatment of Attention Deficit Disorder
BR112019025286A2 (pt) Métodos e composições para tratamento de sonolência excessiva
Coutinho Hemodynamic studies of portal hypertension in schistosomiasis
Jiang et al. Ginsenoside 20 (S)-protopanaxadiol attenuates depressive-like behaviour and neuroinflammation in chronic unpredictable mild stress-induced depressive rats
Zhang et al. Aquaporin-4 deficiency diminishes the differential degeneration of midbrain dopaminergic neurons in experimental Parkinson’s disease
HRP20250166T1 (hr) Mini tablete melatonina i način proizvodnje istih
ES2680921T3 (es) Tetrahidrocannabivarina para uso en el tratamiento de enfermedades inflamatorias intestinales
KR20190073365A (ko) 사이토카인 과분비 및 바이러스성 감염의 치료를 위한 비만 세포 안정화제
HRP20241213T1 (hr) Primjena sepiapterina bez hrane za uporabu u postupku za povećavanje plazmatske izloženosti sepiapterinu
US8916588B2 (en) Methods for treatment of attention deficit hyperactivity disorder
JP2017510607A5 (enExample)
JP2016535780A5 (enExample)
Zhang et al. Rhodioloside ameliorates depressive behavior via up-regulation of monoaminergic system activity and anti-inflammatory effect in olfactory bulbectomized rats
JP2017526693A5 (enExample)
FI3188727T3 (fi) Tasimelteoni smith-magenisin oireyhtymän hoitamiseksi
HRP20200142T1 (hr) Postupci i sastavi za liječenje depresije uporabom ciklobenzaprina
RU2018104691A (ru) Композиции с модифицированным высвобождением ницерголина
AU2021104421A4 (en) Gastrointestinal health composition
JP2019533672A5 (enExample)